EU Approves Roche’s Tecentriq to Treat Non-small Cell Lung Cancer
News
The European Commission (EC) granted marketing authorization to Roche for Tecentriq (atezolizumab) as a monotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior treatment with chemotherapy, the company announced in a press ... Read more